2024
Underuse of Lifesaving Medications for Opioid Use Disorder in US Jails
Springer S. Underuse of Lifesaving Medications for Opioid Use Disorder in US Jails. JAMA Network Open 2024, 7: e2434649. PMID: 39316405, DOI: 10.1001/jamanetworkopen.2024.34649.Peer-Reviewed Original ResearchConsiderations when prescribing opioid agonist therapies for people living with HIV
Tarfa A, Lier A, Shenoi S, Springer S. Considerations when prescribing opioid agonist therapies for people living with HIV. Expert Review Of Clinical Pharmacology 2024, 17: 549-564. PMID: 38946101, PMCID: PMC11299801, DOI: 10.1080/17512433.2024.2375448.Peer-Reviewed Original ResearchMeSH KeywordsAnalgesics, OpioidAnti-HIV AgentsBuprenorphineDelayed-Action PreparationsDelivery of Health CareDrug InteractionsHealth Services AccessibilityHIV InfectionsHumansMethadoneNaltrexoneNarcotic AntagonistsOpiate Substitution TreatmentOpioid-Related DisordersPre-Exposure ProphylaxisUnited StatesConceptsOpioid agonist therapyOpioid use disorderAntiretroviral therapyAgonist therapyDiagnosed OUDOpioid use disorder managementUse disorderTreatment of opioid use disorderExtended-release naltrexonePotential drug interactionsOpioid use disorder treatmentPrescribed opioid agonist therapyLong-acting formulationPre-exposure prophylaxisOUD outcomesImprove HIV preventionIntersection of HIVOpioid antagonistHIV outcomesHIV epidemicOpioidHIVOpioid use disorder servicesPWHHIV preventionSerious Opioid Injection-Related Infection and Initiation of Medication for Opioid Use Disorder
Springer S. Serious Opioid Injection-Related Infection and Initiation of Medication for Opioid Use Disorder. JAMA Network Open 2024, 7: e2421640. PMID: 39046746, DOI: 10.1001/jamanetworkopen.2024.21640.Peer-Reviewed Original ResearchHIV Risk and Interest in Preexposure Prophylaxis in Justice-Involved Persons - Volume 30, Supplement—March 2024 - Emerging Infectious Diseases journal - CDC
Nijhawan A, Pulitzer Z, Torres B, Noreen N, Schultheis A, Frank C, Colon R, Brooks R, Proffitt R, Pankow J, Bennett A, Salyards M, Kuo I, Knight K, Springer S. HIV Risk and Interest in Preexposure Prophylaxis in Justice-Involved Persons - Volume 30, Supplement—March 2024 - Emerging Infectious Diseases journal - CDC. Emerging Infectious Diseases 2024, 30: s68-s74. PMID: 38561803, PMCID: PMC10986824, DOI: 10.3201/eid3013.230739.Peer-Reviewed Original ResearchConceptsHIV riskAssess HIV risk factorsPreexposure prophylaxisPartners of unknown HIV statusMobile health unitReport injection drug useUnknown HIV statusPerceived HIV riskRisk factorsHIV risk factorsRandomized controlled trialsPatient navigationPrEP indicationsInjection drug useHealth unitsJustice-involved personsHIV medicationsHIV statusCondomless sexPrEPEducational effortsDrug useHIVRiskPersons
2023
Integrated Care Models: HIV and Substance Use
Hill K, Kuo I, Shenoi S, Desruisseaux M, Springer S. Integrated Care Models: HIV and Substance Use. Current HIV/AIDS Reports 2023, 20: 286-295. PMID: 37698755, PMCID: PMC11034717, DOI: 10.1007/s11904-023-00667-9.Peer-Reviewed Original ResearchConceptsSubstance use disordersUse disordersSubstance useIntegrated careRecent HIV outbreaksHIV viral suppressionMultidisciplinary care teamHIV virologic suppressionOpioid use disorderRisk of HIVHarm reduction programsSubstance use treatmentEvidence-based strategiesVirologic suppressionViral suppressionHIV outbreakCare teamProvider trainingHIVOnward transmissionHealth outcomesCare servicesClinic leadershipCare integrationMedical literatureEnding the HIV Epidemic for Persons Who Use Drugs: the Practical Challenges of Meeting People Where They Are
Springer S. Ending the HIV Epidemic for Persons Who Use Drugs: the Practical Challenges of Meeting People Where They Are. Journal Of General Internal Medicine 2023, 38: 2816-2818. PMID: 37002460, PMCID: PMC10506995, DOI: 10.1007/s11606-023-08142-2.Peer-Reviewed Original ResearchConceptsHIV epidemicInpatient Low-dose Transitions From Full Agonist Opioids Including Methadone Onto Long-acting Depot Buprenorphine: Case Series From a Multicenter Clinical Trial
Seval N, Nunez J, Roth P, Schade M, Strong M, Frank C, Litwin A, Levin F, Brady K, Nunes E, Springer S. Inpatient Low-dose Transitions From Full Agonist Opioids Including Methadone Onto Long-acting Depot Buprenorphine: Case Series From a Multicenter Clinical Trial. Journal Of Addiction Medicine 2023, 17: e232-e239. PMID: 37579095, PMCID: PMC10368784, DOI: 10.1097/adm.0000000000001136.Peer-Reviewed Original ResearchConceptsOpioid use disorderFull agonist opioidsAgonist opioidsHospital dischargeCase seriesSurgical interventionUse disordersCurrent opioid use disorderInfectious disease physiciansLow-dose strategyMulticenter clinical trialPotential surgical interventionLife-threatening infectionsCOMMIT trialComplex hospitalizationsDepot buprenorphineOpioid relapseUnderused medicationsOpioid withdrawalSublingual buprenorphineBuprenorphine dosesDisease physiciansConcurrent painClinical trialsConcurrent infectionAntiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults
Gandhi R, Bedimo R, Hoy J, Landovitz R, Smith D, Eaton E, Lehmann C, Springer S, Sax P, Thompson M, Benson C, Buchbinder S, del Rio C, Eron J, Günthard H, Molina J, Jacobsen D, Saag M. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults. JAMA 2023, 329: 63-84. PMID: 36454551, DOI: 10.1001/jama.2022.22246.Peer-Reviewed Original ResearchConceptsPrevention of HIVAntiretroviral therapySubstance use disordersAntiretroviral drugsUse disordersCertain antiretroviral medicationsDaily oral regimenInhibitor-containing regimensManagement of comorbiditiesMonkeypox virus infectionDiagnosis of HIVSARS-CoV-2 pandemicCare of peopleGlobal health emergencyInitial therapyOral regimenAdherence supportMetabolic complicationsPreexposure prophylaxisViral suppressionAntiretroviral medicationsOral medicationsHIV infectionLaboratory monitoringInjectable therapies
2022
Maintenance on extended-release naltrexone is associated with reduced injection opioid use among justice-involved persons with opioid use disorder
Lier AJ, Seval N, Vander Wyk B, Di Paola A, Springer SA. Maintenance on extended-release naltrexone is associated with reduced injection opioid use among justice-involved persons with opioid use disorder. Journal Of Substance Use And Addiction Treatment 2022, 142: 108852. PMID: 35988513, PMCID: PMC9509444, DOI: 10.1016/j.jsat.2022.108852.Peer-Reviewed Original ResearchConceptsInjection opioid useOpioid use disorderHepatitis C virusOpioid useXR-NTXOpioid injectionUse disordersDouble-blind placebo-controlled trialExtended-release naltrexonePlacebo-controlled trialCopies/mLIntravenous opioid useTransmission of HIVJustice-involved populationsJustice-involved participantsInjection equipmentHigh treatment groupJustice-involved personsHCV antibodiesHIV RNAPlacebo groupTreat analysisC virusInjection useJustice-involved individualsGender differences among persons entering medication treatment for opioid use disorder in the community
Di Paola A, Taweh N, Biondi BE, Forray A, Frank CA, Shaw A, Springer SA. Gender differences among persons entering medication treatment for opioid use disorder in the community. American Journal On Addictions 2022, 31: 390-395. PMID: 35652902, PMCID: PMC9463117, DOI: 10.1111/ajad.13304.Peer-Reviewed Original ResearchConceptsOpioid use disorderUse disordersQuality of lifeDSM-5 diagnosisPosttraumatic stress disorderOpioid relapseMedication useMedication historyMedication treatmentPsychiatric comorbidityPsychiatric medicationsHigh riskMOUDDepression severityGreater prevalenceGender differencesBaseline assessmentPsychological QoL.Disorder screeningStress disorderMultidisciplinary programGeneralized anxietyWomenMedicationsDisordersStudy protocol of a randomized controlled trial comparing two linkage models for HIV prevention and treatment in justice-involved persons
Springer SA, Nijhawan AE, Knight K, Kuo I, Di Paola A, Schlossberg E, Frank CA, Sanchez M, Pankow J, Proffitt RP, Lehman W, Pulitzer Z, Thompson K, Violette S, Harding KK. Study protocol of a randomized controlled trial comparing two linkage models for HIV prevention and treatment in justice-involved persons. BMC Infectious Diseases 2022, 22: 380. PMID: 35428213, PMCID: PMC9013109, DOI: 10.1186/s12879-022-07354-x.Peer-Reviewed Original ResearchConceptsJustice-involved individualsAntiretroviral treatmentHIV preventionUse disordersStudy participantsStimulant useSubstance use disorder servicesCommunity-based HIVPost-release interventionsPrimary implementation outcomeHIV viral loadPre-exposure prophylaxisOpioid use disorderTreatment of HIVHIV risk behaviorsRisk of HIVSubstance use disordersHigh-risk communitiesHybrid type 1Justice-involved personsHCV testingLinkage interventionHIV careSecondary outcomesART adherenceFactors associated with retention on medications for opioid use disorder among a cohort of adults seeking treatment in the community
Biondi BE, Vander Wyk B, Schlossberg EF, Shaw A, Springer SA. Factors associated with retention on medications for opioid use disorder among a cohort of adults seeking treatment in the community. Addiction Science & Clinical Practice 2022, 17: 15. PMID: 35255967, PMCID: PMC8899775, DOI: 10.1186/s13722-022-00299-1.Peer-Reviewed Original ResearchConceptsOpioid use disorderHigher pain interferenceMOUD retentionPain interferenceUse disordersOngoing prospective cohort studySevere opioid use disorderProspective cohort studyMultivariable logistic regressionCohort of adultsMethadone doseAnalgesic effectBuprenorphine doseCohort studyOpioid useResultsA totalHigher oddsMOUDAdjusted modelHigh doseLogistic regressionBuprenorphineMethadoneDoseDiscontinuationRationale, design and methods of VA-BRAVE: a randomized comparative effectiveness trial of two formulations of buprenorphine for treatment of opioid use disorder in veterans
Petrakis I, Springer SA, Davis C, Ralevski E, Gu L, Lew R, Hermos J, Nuite M, Gordon AJ, Kosten TR, Nunes EV, Rosenheck R, Saxon AJ, Swift R, Goldberg A, Ringer R, Ferguson R. Rationale, design and methods of VA-BRAVE: a randomized comparative effectiveness trial of two formulations of buprenorphine for treatment of opioid use disorder in veterans. Addiction Science & Clinical Practice 2022, 17: 6. PMID: 35101115, PMCID: PMC8802273, DOI: 10.1186/s13722-022-00286-6.Peer-Reviewed Original ResearchConceptsOpioid use disorderVeterans Healthcare AdministrationFormulations of buprenorphineComparative effectiveness trialOpioid useEffectiveness trialUse disordersOpioid epidemicSublingual buprenorphine/naloxoneSevere opioid use disorderBuprenorphine/naloxoneUS opioid epidemicClinical effectiveness trialStandard of careEffective medication treatmentsExtended-release formulationUrgent clinical needLong-term trialsHepatitis BSecondary outcomesSevere sequelaeOpioid abstinencePrimary outcomeMedication treatmentTRIAL REGISTRATION
2021
Feasibility of a community‐based delivery model for HIV pre‐exposure prophylaxis among bar patrons in rural South Africa
Grammatico MA, Moll AP, Choi K, Springer SA, Shenoi SV. Feasibility of a community‐based delivery model for HIV pre‐exposure prophylaxis among bar patrons in rural South Africa. Journal Of The International AIDS Society 2021, 24: e25848. PMID: 34826363, PMCID: PMC8625837, DOI: 10.1002/jia2.25848.Peer-Reviewed Original ResearchConceptsPre-exposure prophylaxisAlcohol Use Disorders Identification TestLargest HIV epidemicCommunity-based delivery modelPrEP uptakeHIV testingOdds ratioOral tenofovir disoproxil fumarate/emtricitabineTenofovir disoproxil fumarate/emtricitabineRural South AfricaHazardous drinkingDisoproxil fumarate/emtricitabineHIV pre-exposure prophylaxisUptake of PrEPHIV care cascadeRapid HIV testingAdjusted odds ratioYoung menRural KwaZulu-Natal ProvinceAlcohol use disorderSexual risk behaviorsDisorders Identification TestBar patronsPrEP deliveryPrEP initiatorsIndividual and poly-substance use and condomless sex among HIV-uninfected adults reporting heterosexual sex in a multi-site cohort
Fredericksen RJ, Whitney BM, Trejo E, Nance RM, Fitzsimmons E, Altice FL, Carrico AW, Cleland CM, Del Rio C, Duerr A, El-Sadr WM, Kahana S, Kuo I, Mayer K, Mehta S, Ouellet LJ, Quan VM, Rich J, Seal DW, Springer S, Taxman F, Wechsberg W, Crane HM, Delaney JAC. Individual and poly-substance use and condomless sex among HIV-uninfected adults reporting heterosexual sex in a multi-site cohort. BMC Public Health 2021, 21: 2002. PMID: 34736425, PMCID: PMC8567631, DOI: 10.1186/s12889-021-12026-7.Peer-Reviewed Original ResearchConceptsLikelihood of CSRecent substance useHIV-negative partnersVaginal sexAnal sexSubstance useHIV-status unknown partnersMultivariable relative risk regressionExposure classificationType of sexHIV-negative adultsPooled effect estimatesPartner's HIV statusMulti-site cohortHigher likelihoodHeterosexual sexRelative risk regressionSingle substance usePoly-substance useHIV-negativeHIV statusRisk regressionPolysubstance useCannabis useSU exposureGender Differences among Criminal Justice-Involved Persons Living with HIV Interested in Extended-Release Naltrexone Treatment
Biondi BE, Frank CA, Forray A, Springer SA. Gender Differences among Criminal Justice-Involved Persons Living with HIV Interested in Extended-Release Naltrexone Treatment. Substance Use & Addiction Journal 2021, 42: 905-911. PMID: 33750285, PMCID: PMC8455717, DOI: 10.1080/08897077.2021.1900984.Peer-Reviewed Original ResearchConceptsSubstance use disordersOpioid use disorderMedication treatmentUse disordersAlcohol use disorderMental health severityXR-NTXAntiretroviral therapyDouble-blind placebo-controlled trialExtended-release naltrexone treatmentExtended-release naltrexonePlacebo-controlled trialCriminal justice-involved personsHealth severityGender differencesCocaine use disorderDrug use severityJustice-involved personsClinical characteristicsART adherenceNaltrexone treatmentTreatment outcomesHigh prevalenceCocaine useHIVCommentary on Murphy et al.: What will it take to prescribe extended‐release naltrexone to treat alcohol use disorder?
Springer SA. Commentary on Murphy et al.: What will it take to prescribe extended‐release naltrexone to treat alcohol use disorder? Addiction 2021, 117: 282-283. PMID: 34549844, DOI: 10.1111/add.15668.Peer-Reviewed Original ResearchLinking criminal justice-involved individuals to HIV, Hepatitis C, and opioid use disorder prevention and treatment services upon release to the community: Progress, gaps, and future directions
Taweh N, Schlossberg E, Frank C, Nijhawan A, Kuo I, Knight K, Springer SA. Linking criminal justice-involved individuals to HIV, Hepatitis C, and opioid use disorder prevention and treatment services upon release to the community: Progress, gaps, and future directions. International Journal Of Drug Policy 2021, 96: 103283. PMID: 34020864, PMCID: PMC8568621, DOI: 10.1016/j.drugpo.2021.103283.Peer-Reviewed Original ResearchConceptsMobile health unitOpioid use disorderHepatitis COUD preventionTreatment servicesInfectious diseasesHepatitis C virus (HCV) managementOpioid use disorder preventionCJ-involved individualsCriminal justice-involved individualsCJ systemHarm reduction servicesImproving HIVCare cascadePatient navigationJustice-involved individualsHealth unitsUse disordersHIVReduction servicesSubstance usePreventionDisorder preventionCommunity agenciesTreatmentHepatitis C in the United States: One Step Forward, Two Steps Back.
Rio CD, Springer SA. Hepatitis C in the United States: One Step Forward, Two Steps Back. American Journal Of Public Health 2021, 111: 768-769. PMID: 33826392, PMCID: PMC8033994, DOI: 10.2105/ajph.2021.306251.Peer-Reviewed Original ResearchLong-acting buprenorphine vs. naltrexone opioid treatments in CJS-involved adults (EXIT-CJS)
Waddell EN, Springer SA, Marsch LA, Farabee D, Schwartz RP, Nyaku A, Reeves R, Goldfeld K, McDonald RD, Malone M, Cheng A, Saunders EC, Monico L, Gryczynski J, Bell K, Harding K, Violette S, Groblewski T, Martin W, Talon K, Beckwith N, Suchocki A, Torralva R, Wisdom JP, Lee JD. Long-acting buprenorphine vs. naltrexone opioid treatments in CJS-involved adults (EXIT-CJS). Journal Of Substance Use And Addiction Treatment 2021, 128: 108389. PMID: 33865691, PMCID: PMC8384640, DOI: 10.1016/j.jsat.2021.108389.Peer-Reviewed Original ResearchConceptsOpioid use disorderSelf-reported opioid useOpioid-positive urine samplesExtended-release buprenorphineExtended-release naltrexoneOpioid overdose eventsXR-NTXOpioid treatmentObservational cohortOpioid useUsual armCare outcomesUse disordersNoninferiority designOverdose eventsUrine samplesBuprenorphineTreatmentAdultsEnhanced treatmentNaltrexoneRCTsCohortU.S. localesTrials